|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Molecular classifications of gastric cancers: Novel insights and possible future applications显示文摘Despite some notable advances in the systemic management of gastric cancer(GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of human epidermal growth factor 2(HER2) inhibitors in combination with chemotherapy, which has soon after become the standard of care for patients with HER2-overexpressing GC. Moreover, oncologists have recognized the clinical utility of conceiving cancers as a collection of different molecularlydriven entities rather than a single disease. Several molecular drivers have been identified as having crucial roles in other tumors and new molecular classifications have been recently proposed for gastric cancer as well. Not only these classifications allow the identification of different tumor subtypes with unique features, but also they serve as springboard for the development of different therapeutic strategies. Hopefully, the application of standard systemic chemotherapy, specifictargeted agents, immunotherapy or even surgery in specific cancer subgroups will help maximizing treatment outcomes and will avoid treating patients with minimal chance to respond, therefore diluting the average benefit. In this review, we aim at elucidating the aspects of GC molecular subtypes, and the possible future applications of such molecular analyses. | Silvio Ken Garattini Debora Basile Monica Cattaneo Valentina Fanotto Elena Ongaro Marta Bonotto Francesca V Negri Rosa Berenato Paola Ermacora Giovanni Gerardo Cardellino Mariella Giovannoni Nicoletta Pella Mario Scartozzi Lorenzo Antonuzzo Nicola Silvestris Gianpiero Fasola Giuseppe Aprile | 2017 | World Journal of Gastrointestinal Oncology2017，9，5： | 5 |
| 2 | Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer:a muhicenter phase Ⅱ study显示文摘 | Ricci S Antonuzzo A Gal l i L | 2000 | Lung Cancer2000，27，2： | 1 |
| 3 | Gemcitabine as monotherapy in elderly patients with advanced non-small cell lung cancer:a multicenter phase II study显示文摘 | Ricci S Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，2： | 1 |
| 4 | Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase Ⅱstudy显示文摘 | Ricci S Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，2： | 1 |
| 5 | Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a maticenter phase Ⅱ study显示文摘 | Ricci S Antonuzzo A Gall L | 2000 | Lung Cancer2000，27，2： | 1 |
| 6 | Gemcitabine monotherapy in elder patients with advanced non-small cell lung cancer:a multicenter phase Ⅱ study显示文摘 | Ricci S Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，： | 1 |
| 7 | Infusion of fluorouracil and leucovorin; Effect of timing and semi-intermittency of drug delivery显示文摘 | Falcone A Allcgrini G Antonuzzo A | 1999 | Oncology1999，57，3： | 1 |
| 8 | Infusion of Fluorouracil and Leucovorin: Effect of Timing and Semi-intermittency of Drug Delivery显示文摘 | Allegrini G Antonuzzo A | 1999 | Oncology1999，57，3： | 1 |
| 9 | Gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer:A multicenter phase Ⅱstudy显示文摘 | Ricci S Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，2： | 1 |
| 10 | First line chemothera-py with planned sequential administration of gemcitabine fol-lowed by docetaxel in elderly advanced non-small-cell lung canc-er patients:a multicenter phase II study显示文摘 | Tibaldi C Vasile E Antonuzzo A | 2008 | Br J Cancer2008，98，： | 1 |
| 11 | Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter phase Ⅱ study显示文摘 | Ricci S Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，2： | 1 |
| 12 | Infusion of fluorouracil and leucovorin effect of timing and semi-intermittency of drug delivery 显示文摘 | Falcone A Allegrini G Antonuzzo A | 1999 | Oncology1999，57，3： | 1 |
| 13 | Gemcitabine as monotherapy in elderly patients with advanced non-small cell lung cancer:a nulticenter phase 2study显示文摘 | Ricci S Antonuzzo A Galii L | 2000 | Lung Cancer2000，27，2： | 1 |
| 14 | Gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer:a multicenter phase Ⅱ study显示文摘 | Ricci S Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，2： | 1 |
| 15 | Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer:a multicenter phase Ⅱ study显示文摘 | Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，2： | 1 |
| 16 | Gemcitabine as monotherapy in elderly patients with advanced non-small cell lung cancer:a multicenter phase Ⅲ study显示文摘 | Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，2： | 1 |
| 17 | Gemcitabine as monotherapy in elderly patients with advanced non -small cell lung cancer, a mul- ticenter phase Ⅱ study 显示文摘 | Ricci S Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，2： | 1 |
| 18 | Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer:a maticenter phase Ⅱ study显示文摘 | Ricci S Antonuzzo A Gall L | 2000 | Lung Cancer2000，27，： | 1 |
| 19 | Gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a multicenter phase Ⅱ study显示文摘 | Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，2： | 1 |
| 20 | Gemcitabine monotherapy in elder patients with advanced non-small cell lung cancer:a multicenter phase Ⅱ study显示文摘 | Ricci S Antonuzzo A Galli L | 2000 | Lung Cancer2000，27，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员